Daily Medication Pearl: Vraylar (Cariprazine)

Article

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Medication Pearl of the Day: Vraylar (Cariprazine)

Indication: Vraylar is an atypical antipsychotic indicated for the treatment of schizophrenia in adults, for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Insight:

  • Dosing: Patients can take Vraylar at 1.5 mg to 6 mg daily.
  • Dosage forms: Capsules of Vraylar come in dosages of 1.5 mg, 3 mg, 4.5 mg, and 6 mg.
  • Adverse events (AEs): Most common AEs include extrapyramidal symptoms and akathisia, extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness.
  • Mechanism of action: The efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.
  • Manufacturer: Forest Laboratories

Source:

vraylar_pi.pdf (allergan.com)

Related Videos
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
Pharmacist helping patient use glucose monitor -- Image credit: Kalyakan | stock.adobe.com
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room - Image credit: pressmaster | stock.adobe.com
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.